Overview

Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease

Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This Phase 1 study will determine the safety, tolerability, and pharmacokinetics of vinorelbine liposomes injection (VLI) in patients with advanced solid tumors, non-Hodgkin's lymphoma, or Hodgkin's disease.
Phase:
Phase 1
Details
Lead Sponsor:
Spectrum Pharmaceuticals, Inc
Treatments:
Vinorelbine